T

TriSalus Life Sciences Inc
NASDAQ:TLSI

Watchlist Manager
TriSalus Life Sciences Inc
NASDAQ:TLSI
Watchlist
Price: 7.305 USD -2.6% Market Closed
Market Cap: 365m USD

TriSalus Life Sciences Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

TriSalus Life Sciences Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
T
TriSalus Life Sciences Inc
NASDAQ:TLSI
Net Issuance of Common Stock
$15.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Flame Acquisition Corp
NYSE:SOC
Net Issuance of Common Stock
$773.8m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Solid Power Inc
NASDAQ:SLDP
Net Issuance of Common Stock
-$8.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Core Scientific Inc
NASDAQ:CORZ
Net Issuance of Common Stock
$59.9m
CAGR 3-Years
389%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Symbotic Inc
NASDAQ:SYM
Net Issuance of Common Stock
$4.9m
CAGR 3-Years
-81%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
Rumble Inc
NASDAQ:RUM
Net Issuance of Common Stock
$663.2k
CAGR 3-Years
-76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

TriSalus Life Sciences Inc
Glance View

Market Cap
364.5m USD
Industry
N/A

TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.

TLSI Intrinsic Value
4.113 USD
Overvaluation 44%
Intrinsic Value
Price
T

See Also

What is TriSalus Life Sciences Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
15.6m USD

Based on the financial report for Dec 31, 2024, TriSalus Life Sciences Inc's Net Issuance of Common Stock amounts to 15.6m USD.

What is TriSalus Life Sciences Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
67%

Over the last year, the Net Issuance of Common Stock growth was 67%.

Back to Top